See more : Daiwa Securities Living Investment Corporation (JRHIF) Income Statement Analysis – Financial Results
Complete financial analysis of Genetron Holdings Limited (GTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genetron Holdings Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Taya Investment Co., Ltd. (TAYA.TA) Income Statement Analysis – Financial Results
- Isgec Heavy Engineering Limited (ISGEC.BO) Income Statement Analysis – Financial Results
- JSC Halyk Bank (HSBK.IL) Income Statement Analysis – Financial Results
- Caina Technology Co., Ltd. (301122.SZ) Income Statement Analysis – Financial Results
- GOCL Corporation Limited (GOCLCORP.NS) Income Statement Analysis – Financial Results
Genetron Holdings Limited (GTH)
About Genetron Holdings Limited
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 650.71M | 531.95M | 424.49M | 323.43M | 225.18M | 101.03M |
| Cost of Revenue | 369.28M | 193.98M | 164.27M | 178.44M | 132.45M | 74.21M |
| Gross Profit | 281.43M | 337.97M | 260.22M | 144.99M | 92.73M | 26.82M |
| Gross Profit Ratio | 43.25% | 63.53% | 61.30% | 44.83% | 41.18% | 26.55% |
| Research & Development | 290.29M | 253.95M | 149.00M | 91.70M | 71.41M | 45.78M |
| General & Administrative | 266.91M | 227.00M | 126.32M | 117.17M | 88.23M | 45.49M |
| Selling & Marketing | 364.56M | 343.16M | 246.96M | 253.56M | 182.47M | 94.57M |
| SG&A | 631.47M | 570.16M | 373.28M | 370.73M | 270.71M | 140.06M |
| Other Expenses | -8.71M | -5.33M | -8.53M | -10.85M | -233.63M | -258.11M |
| Operating Expenses | 913.05M | 818.78M | 513.75M | 451.58M | 332.19M | 181.01M |
| Cost & Expenses | 1.28B | 1.01B | 678.02M | 630.01M | 464.64M | 255.22M |
| Interest Income | 2.86M | 20.50M | 28.33M | 441.00K | 1.55M | 513.00K |
| Interest Expense | 111.49M | 5.25M | 5.63M | 5.40M | 0.00 | 669.00K |
| Depreciation & Amortization | 85.39M | 20.50M | -2.80B | -319.22M | 27.86M | 20.61M |
| EBITDA | -651.24M | -460.32M | -201.69M | -625.81M | -212.21M | -134.08M |
| EBITDA Ratio | -83.94% | -86.53% | -718.18% | -193.49% | -197.04% | -397.06% |
| Operating Income | -631.62M | -480.82M | -253.53M | -306.59M | -232.98M | -152.54M |
| Operating Income Ratio | -97.07% | -90.39% | -59.73% | -94.79% | -103.46% | -150.98% |
| Total Other Income/Expenses | -108.69M | 21.04M | -2.80B | -366.94M | -225.53M | -268.10M |
| Income Before Tax | -810.63M | -502.60M | -3.07B | -676.03M | -464.99M | -420.64M |
| Income Before Tax Ratio | -124.58% | -94.48% | -723.00% | -209.02% | -206.50% | -416.34% |
| Income Tax Expense | 73.26M | -64.19M | -2.87B | -354.54M | -232.02M | -257.44M |
| Net Income | -883.89M | -438.40M | -198.11M | -321.49M | -464.99M | -420.64M |
| Net Income Ratio | -135.84% | -82.41% | -46.67% | -99.40% | -206.50% | -416.34% |
| EPS | -9.53 | -4.76 | -3.29 | -4.65 | -6.73 | -6.22 |
| EPS Diluted | -9.53 | -4.76 | -3.29 | -4.65 | -6.73 | -6.22 |
| Weighted Avg Shares Out | 92.80M | 92.11M | 60.28M | 69.07M | 69.07M | 67.68M |
| Weighted Avg Shares Out (Dil) | 92.80M | 92.11M | 60.28M | 69.07M | 69.07M | 67.68M |
Genetron Holdings: Solid Revenue Growth Continues While Earnings Move Toward Profitability
Genetron Holdings Limited (GTH) CEO Sizhen Wang on Q1 2021 Results - Earnings Call Transcript
Genetron Health Reports First Quarter 2021 Unaudited Financial Results
Genetron Holdings (GTH) Stock: Over 10% Increase Explanation
Genetron Health Announces Strategic Partnership with JD Health to Create Innovative Solutions for Full-cycle Cancer Management
3 Small Cap Stocks That Are Short Squeeze Candidates
Genetron Health Announces Strategic Partnership with Siemens Healthineers to Promote Precision Oncology for Lung Cancer
Genetron Health to Announce First Quarter 2021 Financial Results and Host Investor Call on May 24, 2021
Genetron Health to Present at Upcoming Investor Conferences
Genetron Health Releases 22 New Research Results at American Association for Cancer Research Annual Meeting (AACR) 2021
Source: https://incomestatements.info
Category: Stock Reports